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Topic 06 – Hypertension / Vascular disease
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The stress test as a diagnostic toolfor coronary artery disease in
hypertensive patients
Samia Benghazi, Dalila Baghdadi, Rachida Habbal
CHU Ibn Rochd, Cardiologie, Casablanca, Maroc
Introduction: In hypertensive patients, there are multiplecauses of error in
the diagnosis of coronary artery disease: The objective of this study was to
evaluate the sensitivity of the positive electrical criteria in the stress test in
diagnosing coronary artery disease within the hypertensive patients. 
Materials/Methods: 120 hypertensive patients with positive stress test
underwent coronary angiography. 
Results: 33 % of patients had significant coronary lesions and 67% had
normal coronary angiography. Two groups of patients were identified:
group A ( 77 patients ) withST segment depression in DII, DIII, aVF and V6
with maximal effort and group B ( 43 patients ) with a ST segment depression
in DII, DIII, aVF and/or V4, V5, V6 with maximal effort. In group A,
65 patients (84.4%) had normal coronary angiography. In group B, 31 patients
(72%) had significant coronary lesions. In a subgroup of 46 patients in group
A with persistent ST segment depression in V4 to V6 and recovering for 4 to
6 minutes, 93% of coronary angiograms were normal. In another subgroup of
19 patients in group B with persistent ST segment depressionin V4 to V6 and
recovering for 4 to 8 minutes, 16 patients (86%) had significant lesions on
coronary angiograms. 
Conclusion: hypertensive patients with stress test showing ST segment
depression in DII, DIII, aVF and/or V4, V5, V6 on maximum effort and per-
sisting for 4-8 minutes recovering have a high probability of significant coro-
nary artery disease.
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Few data exists regarding the systemic safety of intravitreal anti-VEGF
monoclonal antibodies (MAb) use in people with neovascular age-related
macular degeneration (AMD), diabetic macular oedema (DMO) or retinal vein
occlusions (RVO). We performed a systematic review and meta-analysis to
evaluate the risk of major cardiovascular (MCE) and nonocular hemorrhagic
(NHE) events in AMD, DMO or RVO patients receiving intravitreal anti-
VEGF MAb. We included randomized controlled trials (RCT) comparing
ranibizumab or bevacizumab to no treatment or non-anti-VEGF treatments, or
ranibizumab to bevacizumab, in AMD, DMO or RVO patients. We used fixed
effect model and reported results as odds-ratios and their 95% CI. Primary
endpoints were major cardiovascular and nonocular hemorrhagic events.
Results: 21 RCT were retrieved (9557 patients). Anti-VEGF-MAb did not
significantly increase the risk of MCE events (1.18 [0.81, 1.71]) or NHE (1.42
[0.95, 2.13]) when compared to control. Bevacizumab did not increase the risk
of MCE (0.94 [0.59, 1.52]) or NHE (2.56 [0.78, 8.38]) when compared to
ranibizumab, but significantly increased Venous Thromboembolic Events (VTE
3.45 [1.25, 9.54]). Subgroup analysis showed a significant increase of NHE in
AMD patients in ranibizumab vs control (1.57 [1.01, 2.44]). Anti-VEGF-MAb
did not significantly increased overall mortality (1.53 [0.92, 2.56]), cardiovas-
cular mortality (1.29 [0.70, 2.37]), stroke (1.61 [0.85, 3.05]), MI (0.92 [0.54,
1.59]), VTE (1.39, [0.17, 11.38]), or hypertension (0.97 [0.71, 1.32]). 
Conclusions: the available clinical evidence showed that anti-VEGF-
MAbs were not associated with significant increases in risks of MCE or NHE,
but studies and meta-analysis were not powered enough to correctly assess
these risks. Increased risks of VTE with bevacizumab and nonocular hemor-
rhagic events in older AMD patients with ranibizumab should also be cau-
tiously interpreted, as more safety data are needed 
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Is the measurement of carotid-femoral pulse wave velocity useful in
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Purpose: The carotid-femoral pulse-wave velocity (cfPWV) is predictive
for cardiovascular events in general population and in patients with coronary
artery disease (CAD). Patients with peripheral artery disease (PAD) are high
cardiovascular risk, but the interest of cfPWV has never been assessed in this
case. We sought to compare cfPWV in severe cases of PAD and CAD, and to
assess its prognostic value in the former group. 
Methods: From 01/12 to 06/13 we measured cfPWV in patients referred to our
hospital either for CABG or for limb revascularization for severe PAD. Patients
with CAD with ankle-brachial index <0.90 were excluded. In PAD patients, base-
line data and risk factors were compared in those with cfPWV>10m/s vs. those
≤10m/s. During follow-up, the following outcomes were collected: death, amputa-
tion and MACE (death, or stroke or myocardial infarction). 
Results: We studied 162 patients (76 with PAD and 86 with CAD, age 69
vs. 67 yrs, p=0.25), with similar sex and risk factors distribution, except for
diabetes (54% vs 20%, p<0.05). PAD patients had higher cfPWV than those
with CAD (11.3±3.7 vs. 9.8±3.0m/s, p<0.007). In patients with PAD, 50%
had a cfPWV>10m/s. These patients were older (72 vs. 66 yrs, p<0.001) with
higher rates of diabetes (76% vs 56%, p<0.001) than PAD patients with
cfPWV ≤10m/s, but did not differ regarding other risk factors. The cfPWV
was found lower in the presence of aorto-iliac disease than in case of more
distal PAD (9.5±2.5 vs. 11.8±3.9m/s, p<0.001). During follow-up of 10.5±5.7
months of PAD patients, 17.1% deceased, 5.3% had amputation, and MACE
occurred in 19.7% of cases. We found no association between cfPWV and
events (HR for death: 0.95, p=0.28; HR for amputation: 1.02, p=0.65; HR for
MACE: 0.98, p=0.29). 
Conclusion: Patients with PAD have stiffer aorta than those with CAD, as
assessed by cfPWV, in part due to higher rates of diabetes. However cfPWV
is not prognostic in patients PAD. The lower cfPWV in patients with aorto-
iliac disease may suggest measurement issues, as this velocity may be
decreased because of severe stenosis on the pulse wave trajectory. 
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Objectives: in patient free from overt cardiac disease and conduction dis-
orders, R wave in aVL lead (RaVL) is better correlated than other ECG
indexes with left ventricular mass index (LVMI) assessed with transthoracic
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